OGXI 2.13 Oncogenex Pharmaceuticals Inc $OGXI Hit a 52 week

New Post Public Reply Private Reply Replies (0) Message Board

Nov 10, 2014 at 10:48 PM

OGXI 2.13 Oncogenex Pharmaceuticals Inc $OGXI Hit a 52 week low of 2.08 Closing the day 11/10/14 at 2.13 -0.05 -2.29% With a day low of 2.08 and a total volume of 83,084.

OGXI Recent Posts: http://investorshangout.com/Oncogenex-Pharmac...GXI-54968/

OGXI Oncogenex Pharmaceuticals Inc Recent Headline News

Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 327.87 (+7.12), ALNY: 99.18 (+3.34), ISIS: 47.23 (+2.64), OGXI: 2.13 (-0.05), TEVA: 58.04 (+0.34), RGLS: 20.91 (-1.17), GSK: 45.16 (+0.25), SNY: 46.19 (+0.50)

Biotech Watchlist Update: Small-Cap Biotechs Struggle, But Investors Remain Enchanted By Big Pharma's Returns
Life Sciences Report - Seeking Alpha - Fri Nov 07, 8:16AM CST
When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies haven't yet entirely recouped the losses. The performance...
CERS: 4.03 (+0.02), PCYC: 133.98 (+0.49), CLDX: 14.81 (+1.39), INCY: 70.96 (+1.64), BIND: 9.64 (+0.42), CELG: 108.01 (+1.56), OMER: 17.49 (+0.12), VSTM: 9.08 (+0.05), GILD: 107.02 (+0.57), OGXI: 2.13 (-0.05), ANTH: 1.84 (unch), NVAX: 5.21 (+0.26)

OncoGenex Pharmaceuticals' (OGXI) CEO Scott Cormack on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sun Nov 02, 3:04AM CST

OGXI: 2.13 (-0.05)

More on OncoGenex Pharmaceuticals Q3 results
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 1:32PM CDT

OGXI: 2.13 (-0.05)

OncoGenex Pharmaceuticals beats by $0.14, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 3:34PM CDT

OGXI: 2.13 (-0.05)

OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2014
CNW Group - Thu Oct 30, 3:01PM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided a summary of clinical developments and announced third quarter 2014 financial results.
OGXI: 2.13 (-0.05), TEVA: 58.04 (+0.34)

Some Of Soros' Stocks Surged Today, While Others Soured
at The Street - Wed Oct 29, 3:31PM CDT
OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI), MCG Capital Corp (NASDAQ:MCGC) and Doral Financial Corp. (NYSE

RL) made noteworthy gains on the market this Wednesday. In the red today are Cal Dive In...
OGXI: 2.13 (-0.05), MCGC: 3.66 (unch), INVN: 14.95 (-0.25), DRL: 5.13 (-0.37), ARCP: 8.50 (-0.29)

OncoGenex reports on October 30
Seeking Alpha - at Seeking Alpha - Thu Oct 16, 9:27AM CDT

OGXI: 2.13 (-0.05)

OncoGenex to Report Financial Results for Third Quarter 2014 on October 30, 2014
PR Newswire - Thu Oct 16, 5:30AM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's third quarter 2014 financial results will be released on Thursday, October 30, 2014, and that the Company will host a conference call and live webcast at 4:30 p.m. ET that afternoon. Management will provide an overview of the company's financial results, development programs and a general business update.
OGXI: 2.13 (-0.05)

OncoGenex's Phase III Prostate Cancer Study Fully Enrolled - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 4:11PM CDT
OncoGenex Pharmaceuticals, Inc. (OGXI) has finished enrolling patients in a phase III study (AFFINITY) on custirsen for metastatic castrate-resistant prostate cancer.
LCI: 51.81 (+1.64), ENDP: 68.87 (-0.09), OGXI: 2.13 (-0.05), TEVA: 58.04 (+0.34)

5 Stocks Under $10 to Trade for Breakouts
at The Street - Thu Sep 18, 6:00AM CDT
These under-$10 stocks are within range of triggering breakout trades.
NLST: 0.74 (-0.02), ANY: 8.53 (-0.03), OGXI: 2.13 (-0.05), GLYC: 7.99 (+0.08)

OncoGenex Announces Completion of Patient Enrollment in the Phase 3 AFFINITY Trial of Custirsen in Combination with Cabazitaxel/Prednisone as Second-line Chemotherapy in Men with Metastatic Castrate-Resistant Prostate Cancer
PR Newswire - Tue Sep 16, 5:30AM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that patient enrollment has been completed in the Phase 3 AFFINITY trial.
OGXI: 2.13 (-0.05), TEVA: 58.04 (+0.34)

4 Under-$10 Biotech Stocks in Breakout Territory
at The Street - Wed Aug 27, 6:00AM CDT
These biotech stocks trading for less than $10 a share are within range of triggering breakout trades.
OGXI: 2.13 (-0.05), ARTX: 2.93 (+0.01), CYTR: 2.85 (-0.02), CNCE: 13.37 (+0.27)

OncoGenex's Custirsen Passes First Interim Futility Analysis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 4:40PM CDT
OncoGenex Pharmaceuticals, Inc. (OGXI) announced that the IDMC has recommended the continuation of the phase III ENSPIRIT study on custirsen for lung cancer.
ENDP: 68.87 (-0.09), OGXI: 2.13 (-0.05), UTHR: 125.17 (+0.96), TEVA: 58.04 (+0.34)

OncoGenex Announces Update on Phase 3 ENSPIRIT Trial Evaluating Custirsen in Advanced Non-Small Cell Lung Cancer
PR Newswire - Thu Aug 21, 3:01PM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Phase 3 ENSPIRIT trial, evaluating custirsen in the treatment of non-small cell lung cancer (NSCLC), is continuing as planned per the recommendation of the Independent Data Monitoring Committee (IDMC) based upon completion of the first interim futility analysis.
OGXI: 2.13 (-0.05), TEVA: 58.04 (+0.34)

OncoGenex Q2 Loss Narrower than Expected, Revenues Down Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 3:00PM CDT
OncoGenex Pharmaceuticals, Inc. (OGXI) reported a loss of 47 cents per share, narrower than the the Zacks Consensus Estimate of a loss of 49 cents.
AGN: 195.24 (-0.76), OGXI: 2.13 (-0.05), AZN: 73.21 (+0.33), TEVA: 58.04 (+0.34)

Achieve Life Sciences (ACHV) Stock Research Links

ACHV Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Epsilor Launches Cutting-Edge 6T Battery for Military Use

A Big Leap for Military Power on the Go Seems like Epsilor just raised the stakes in the military tech race with their latest 6T battery, a piece of kit boasting some serious muscle at 4,400Wh with 174Ah thrown in for good measure. Serving up a military-grade solution where endurance and performance are necessities, they've entered production just in time for the...

Veteran Suicide Prevention: The Urgency Behind CVN's Push

Veteran suicide is a crisis staring us square in the face, with rates 60% higher than the general population. It's a grim reminder that the mental toll on those who've served is a deep chasm hard to bridge. Cohen Veterans Network (CVN) is stepping up to the plate with a new campaign dubbed 'Ask Anyway: Conversations to Save a Life'. This isn't just any awareness...

Hyperscale Recalibrates: AI Boom or Risky Bet?

Is Hyperscale Making the Right Move? Hyperscale Data, Inc. waved goodbye to the Bitcoin mining days to clear the stage for artificial intelligence (AI). But is this strategic leap off the blockchain and into AI territory as golden as promised? Whisper around the street is it could turn into a $3 billion windfall. But let's chew through the details before toasting...

UNISORB Expands Reach with BILZ Acquisition

UNISORB Acquisition: A Game-Changer for Industrial Solutions This ain't the first time a company took over another to expand its footprint, but UNISORB's latest move to scoop up BILZ-USA is worth a closer look. Everybody's talking about this takeover that throws UNISORB right into the spotlight of North America's industrial sector. Naming them the exclusive distributor of...

AEC Firms Revamp Strategies Amid Talent Tug-of-War

The State of Compensation in AEC Sit back and chew on this—AEC firms are playing a whole new ball game when it comes to compensating their talent. FMI Corporation’s 2026 Compensation Trends Study is putting a spotlight on what really goes on behind the scenes in architecture, engineering, and construction firms. This is about more than just tossing some coin for a...

Lindian's Bold Leap into Rare Earths Processing

Changing the Game in Rare Earths When Lindian Resources announces a partnership, it's not just window dressing. This time, they've linked arms with Carester SAS for a hefty venture into oxide separation. The scope? An 8,000-tonne REO facility in Kazakhstan, a place already stamped as a geological treasure chest. We're staring at what could potentially be a new dawn for...

Empirik.ai's $21M for AI in Infrastructure Revolution

AI-Powered Infrastructure Takes the Stage Well, here's a tech gambit going full steam: empirik.ai just hit the digital scene with a $21 million war chest. Fresh out of the stealth shadows, they've got big names like Sequoia Capital, S32, Canapi Ventures, and Alumni Ventures stamping their ticket. What's the fuss? They're rolling out the first AI agent designed to...

ZPMC Names Two New 38,000 DWT Vessels for Chipolbrok

Navigating Uncharted Waters with New Vessels Some days, you see a giant leap in an industry and think, "Well, someone's got ambition." Here, we're talking about ZPMC's gutsy naming ceremony for two spanking new 38,000 DWT multipurpose heavy-lift ships destined for Chipolbrok, happening fresh off the docks in Shanghai. Specifications That Make Waves Imagine a vessel the...

BlueSky Enters Nashville: In-Home Vet Care Begins

Nashville Welcomes A New Wave of Pet Care In a world where convenience is king, BlueSky At-Home Veterinary Care is stepping up to the plate—or should I say, doorstep—by rolling out its fresh take on veterinary services in Nashville. Kicking off on September 15, 2026, this isn't just any ol' run-of-the-mill clinic opening. We're talking about vets coming straight to...

CGX Hits Big Stage with New Obstacle Racing Shoes

A Bold Step into Obstacle Racing Today, CGX is shaking things up in the world of obstacle racing. The Chinese footwear brand launched its CGX&OCR R1010 and R1020 shoes right at the UIPM 2026 Obstacle World Championships in Beijing. Talk about a grand entrance. Targeting high-stakes international competition, these shoes are set to redefine how athletes tackle those...